Our clinical pipeline of
kinase inhibitors includes
tumor-targeted therapies
and immuno-targeted
Tumor-Targeted Therapies

Tumor-targeting therapies block the growth and spread of cancer cells by targeting and interfering with specific pro-tumoral cancer mechanisms within the tumor cell, thereby advancing cancer treatment beyond non-specific chemotherapies that affect all rapidly dividing cells.

The Receptor Tyrosine Kinases on the surface of the cell (KIT, MET, TRK, CSF1R, TIE2) activate cell signaling by engaging their respective Ligands (SCF, HGF, NGF, CSF1, ANG). Each Ligand/Receptor Tyrosine Kinase interaction activates two main signaling cascades—the “survival cascade” and the “growth cascade”— that drive cancer growth or suppress the tumor immune response. Deciphera’s tumor-targeted and immuno-targeted therapies selectively inhibit these receptor tyrosine kinases.


DCC-2618 is a spectrum selective inhibitor of wild-type and mutant KIT kinases.

in clinical development for genetically-defined cancers, including gastrointestinal tract stromal tumors (GIST) and other KIT-driven cancers such as systemic mastocytosis.

DCC-2618 provides broad mutant coverage, including aggressive exon mutations such as exon 17, offering the potential for improved clinical outcomes.  In cell culture studies, DCC-2618 and related switch control KIT inhibitors are very resilient to development of mutational resistance, suggesting that their anticancer effects will be longer-lasting than previous therapies.

Back to Top